Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. [Epub ahead of print]

PMID:
30635634
2.

New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.

Bar-Natan M, Hoffman R.

Haematologica. 2019 Jan;104(1):3-6. doi: 10.3324/haematol.2018.205989. No abstract available.

3.

Management of Intraoperative Coagulopathy.

Bar-Natan M, Hymes KB.

Neurosurg Clin N Am. 2018 Oct;29(4):557-565. doi: 10.1016/j.nec.2018.06.007. Review.

PMID:
30223968
4.

MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.

Stroopinsky D, Rajabi H, Nahas M, Rosenblatt J, Rahimian M, Pyzer A, Tagde A, Kharbanda A, Jain S, Kufe T, Leaf RK, Anastasiadou E, Bar-Natan M, Orr S, Coll MD, Palmer K, Ephraim A, Cole L, Washington A, Kufe D, Avigan D.

J Cell Mol Med. 2018 May 15. doi: 10.1111/jcmm.13662. [Epub ahead of print]

5.

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.

Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D.

Leukemia. 2017 Dec;31(12):2780-2790. doi: 10.1038/leu.2017.163. Epub 2017 May 30.

6.

Extended Small-Dose Platelet Transfusions in Multitransfused Hemato-Oncological Patients: A Single-Center Experience.

Gurevich-Shapiro A, Tzadok S, Rosenberg A, Inbal A, Bar-Natan M, Wolach O, Raanani P.

Acta Haematol. 2017;137(4):183-190. doi: 10.1159/000465510. Epub 2017 Apr 19.

PMID:
28419992
7.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D.

Br J Haematol. 2017 Mar;176(6):929-938. doi: 10.1111/bjh.14493. Epub 2017 Jan 20.

8.

Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.

Xiang M, Kim H, Ho VT, Walker SR, Bar-Natan M, Anahtar M, Liu S, Toniolo PA, Kroll Y, Jones N, Giaccone ZT, Heppler LN, Ye DQ, Marineau JJ, Shaw D, Bradner JE, Blonquist T, Neuberg D, Hetz C, Stone RM, Soiffer RJ, Frank DA.

Blood. 2016 Oct 6;128(14):1845-1853. doi: 10.1182/blood-2015-07-660506. Epub 2016 Aug 16.

9.

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D.

Blood. 2015 Jul 16;126(3):354-62. doi: 10.1182/blood-2015-02-628149. Epub 2015 Jun 5.

10.

High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?

Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, Shpilberg O, Douer D, Tallman MS, Raanani P.

Hematol Oncol. 2016 Mar;34(1):28-35. doi: 10.1002/hon.2191. Epub 2015 Feb 17.

PMID:
25689584
11.

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL.

Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.

12.

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD.

Blood. 2014 May 1;123(18):2816-25. doi: 10.1182/blood-2013-02-481507. Epub 2014 Feb 26.

13.

Immunotherapy for multiple myeloma.

Rosenblatt J, Bar-Natan M, Munshi NC, Avigan DE.

Expert Rev Hematol. 2014 Feb;7(1):91-6. doi: 10.1586/17474086.2014.878226. Epub 2014 Jan 13. Review.

PMID:
24417573
14.

A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD.

Clin Cancer Res. 2014 Mar 1;20(5):1135-45. doi: 10.1158/1078-0432.CCR-13-0956. Epub 2013 Nov 27.

15.

Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.

Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L, Lahav M, Yeshurun M, Shpilberg O, Herscovici C, Wolach O, Itchaki G, Bar-Natan M, Vidal L, Gafter-Gvili A, Raanani P.

Am J Hematol. 2014 Mar;89(3):243-8. doi: 10.1002/ajh.23622.

16.

Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?

Adamia S, Pilarski PM, Bar-Natan M, Stone RM, Griffin JD.

Curr Cancer Drug Targets. 2013 Sep;13(7):735-48. Review.

PMID:
23906050
17.

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA.

Genes Cancer. 2012 Jul;3(7-8):503-11. doi: 10.1177/1947601912466555.

18.

Early death in patients diagnosed with non-Hodgkin's lymphoma.

Bairey O, Bar-Natan M, Shpilberg O.

Ann Hematol. 2013 Mar;92(3):345-50. doi: 10.1007/s00277-012-1623-y. Epub 2012 Nov 17.

PMID:
23161388
19.

STAT signaling in the pathogenesis and treatment of myeloid malignancies.

Bar-Natan M, Nelson EA, Xiang M, Frank DA.

JAKSTAT. 2012 Apr 1;1(2):55-64. doi: 10.4161/jkst.20006. Review.

20.

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.

Bar-Natan M, Nelson EA, Walker SR, Kuang Y, Distel RJ, Frank DA.

Leukemia. 2012 Jun;26(6):1407-10. doi: 10.1038/leu.2011.338. Epub 2011 Dec 2. No abstract available.

PMID:
22134716
21.

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.

Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA.

Blood. 2011 Mar 24;117(12):3421-9. doi: 10.1182/blood-2009-11-255232. Epub 2011 Jan 13.

22.

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7. doi: 10.1073/pnas.0911726107. Epub 2009 Dec 15.

23.

Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.

Bar-Natan M, Nagler A.

Isr Med Assoc J. 2006 Mar;8(3):205-7. No abstract available.

24.

Confirmation of the association between male pattern baldness and the androgen receptor gene.

Levy-Nissenbaum E, Bar-Natan M, Frydman M, Pras E.

Eur J Dermatol. 2005 Sep-Oct;15(5):339-40.

PMID:
16172040
25.

Sternoclavicular infectious arthritis in previously healthy adults.

Bar-Natan M, Salai M, Sidi Y, Gur H.

Semin Arthritis Rheum. 2002 Dec;32(3):189-95. Review.

PMID:
12528083
26.

[Massive pulmonary embolism: an update on management].

Bar-Natan M, Sidi Y, Gur H.

Harefuah. 2001 Jul;140(7):640-3. Review. Hebrew. No abstract available.

PMID:
11481971
27.

Postoperative nasogastric decompression: a prospective randomized trial.

Montgomery RC, Bar-Natan MF, Thomas SE, Cheadle WG.

South Med J. 1996 Nov;89(11):1063-6.

PMID:
8903288
28.

Delayed gastric emptying after gastric surgery.

Bar-Natan M, Larson GM, Stephens G, Massey T.

Am J Surg. 1996 Jul;172(1):24-8.

PMID:
8686797
29.

Haemophilus pneumonia is a common cause of early pulmonary dysfunction following trauma.

Spain DA, Wilson MA, Boaz PW, Bar-Natan MF, Garrison RN.

Arch Surg. 1995 Nov;130(11):1228-31; discussion 1231-2.

PMID:
7487467
30.

Tube thoracostomy. Factors related to complications.

Etoch SW, Bar-Natan MF, Miller FB, Richardson JD.

Arch Surg. 1995 May;130(5):521-5; discussion 525-6.

PMID:
7748091
31.

Platelet-activating factor and sepsis-induced small intestinal microvascular hypoperfusion.

Bar-Natan MF, Wilson MA, Spain DA, Garrison RN.

J Surg Res. 1995 Jan;58(1):38-45.

PMID:
7830404
32.

Laparoscopic excision of a carcinoid tumor of the appendix.

Bar-Natan MF, Saxe A, Phillips E.

Gastrointest Endosc. 1994 Jul-Aug;40(4):525-6. No abstract available.

PMID:
7926560
33.

Role of nitric oxide in the small intestinal microcirculation during bacteremia.

Spain DA, Wilson MA, Bar-Natan MF, Garrison RN.

Shock. 1994 Jul;2(1):41-6.

PMID:
7537619
34.

Nitric oxide synthase inhibition aggravates intestinal microvascular vasoconstriction and hypoperfusion of bacteremia.

Spain DA, Wilson MA, Bar-Natan MF, Garrison RN.

J Trauma. 1994 May;36(5):720-5.

PMID:
7514673
35.

Villous adenoma of the duodenal bulb.

Bar-Natan M, Phillips E, Dale R, Grossman D, Saxe A.

Am J Gastroenterol. 1993 Jul;88(7):1120-1. No abstract available.

PMID:
8317418

Supplemental Content

Loading ...
Support Center